Replay available

LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call

LeMaitre Vascular, Inc. (NASDAQ: LMAT) Q1 2025 earnings conference call, held 2025-05-15. Replay captured from the company's public earnings webcast.

Thu, May 15, 2025 at 5:00 PMendedReplay
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Michael Saccone

Analyst, Jefferies

Dorian LeBlanc

Chief Financial Officer

George LeMaitre

Chief Executive Officer

Jim Sidoti

Analyst, Sidoti & Co.

Dave Roberts

President

Ross Osborne

Analyst, Cantor Fitzgerald

Brett Fishman

Analyst, KeyBank Capital Markets

Rick Wise

Analyst, Stiefel

Frank Tarkinan

Analyst, Lake Street Capital Markets

Danny Stoddard

Analyst, Citizens JMP

Replay transcript excerpt

Welcome to the LeMaitre Vascular first quarter 2025 financial results conference call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. Dorian LeBlanc, Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir. Thank you, operator. Good afternoon, and thank you for joining us on our Q1 2025 conference call. With me on today's call is our CEO, George LeMaitre, and our President, Dave Roberts. Before we begin, I'll read our safe harbor statement. Today we will make some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify these forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today May 1, 2025, and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and subsequent SEC filings, including disclosure of the factors that could cause results to differ materially from those expressed or implied. During this call, we will discuss non-GAAP financial measures, such as organic sales A reconciliation of GAAP to non-GAAP measures discussed in this call is contained in the associated press release and is available in the investor relations section of our website, www.lemate.com. I'll now turn the call over to George Lemaitre. Thanks, Dorian. Q1 sales were stronger than our February 27th guidance. 13% organic and 12% reported growth was led by graphs up 17%...

More from Lemaitre Vascular, Inc.